NCT03288363 (tDCS-AD) is a NA clinical trial of tDCS in Alzheimer Disease, sponsored by Benjamin CALVET.

Who is sponsoring NCT03288363?

NCT03288363 is sponsored by Benjamin CALVET.

What drugs are being tested in NCT03288363?

Interventions in NCT03288363: tDCS.

What condition does NCT03288363 study?

NCT03288363 studies Alzheimer Disease.

Is NCT03288363 still recruiting?

NCT03288363 is currently status unknown. Last updated 22 October 2021.

Last reviewed 2021-10-22 · How we verify

NCT03288363: tDCS-AD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Transcranial Direct Current Stimulation and Early Alzheimer's Disease (tDCS-AD)

Status unknown NA Last updated 22 October 2021

What this trial tests

NA trial testing tDCS in Alzheimer Disease in 80 participants. Status unknown.

Timeline

6 June 2017

Primary endpoint
6 June 2024

6 December 2024

Quick facts

Lead sponsor	Benjamin CALVET
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	80
Start date	6 June 2017
Primary completion	6 June 2024
Estimated completion	6 December 2024
Sites	1 location across France

Drugs / interventions tested

tDCS — full drug profile →

Conditions studied

Alzheimer Disease — all drugs for Alzheimer Disease →

Sponsor

Benjamin CALVET

Who can join

18 and older, any sex, with Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

TDCS is a rapidly expanding technique, used to treat cognitive difficulties associated with many pathologies (Parkinson's disease, rehabilitation after head trauma, etc.), but which remains of the field of research. Its use remains very experimental, and concerns the exploration of cognitions, in healthy and diseased subjects. There are not many studies on the elderly subject with Alzheimer's disease, nor do they document the medium- and long-term effect (more than one month), nor the effect on geriatric parameters such as Fragility indices and the risk of falls, especially at home. These characteristics are decisive because they define the level of autonomy. The investigators therefore wish to study the effect of a 2-week treatment with tDCS (tDCS active) versus placebo (2-week tDCS group) for a three-month period.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Alzheimer's disease drug development pipeline: 2019.
Cummings J, Lee G, Ritter A, Sabbagh M, et al · · 2019 · cited 485× · PMID 31334330 · DOI 10.1016/j.trci.2019.05.008
Modulation of Brain Hyperexcitability: Potential New Therapeutic Approaches in Alzheimer's Disease.
Toniolo S, Sen A, Husain M. · · 2020 · cited 74× · PMID 33297460 · DOI 10.3390/ijms21239318
Therapy for Alzheimer's disease: Missing targets and functional markers?
Stoiljkovic M, Horvath TL, Hajós M. · · 2021 · cited 52× · PMID 33711510 · DOI 10.1016/j.arr.2021.101318
The Potential for Neuromodulation in the Treatment of Alzheimer's Disease: A Review of Clinical Trials.
Jones T, Shalom M, Chalamgari A, Gold J, et al · · 2025 · PMID 40599507 · DOI 10.7759/cureus.85156

Verify or expand the search:

Other trials of tDCS

Trials testing the same drug.

NCT07400939 — Brain Stimulation Combined With Watching Hand Movements to Improve Hand Recovery in Chronic Stroke · NA · recruiting
NCT06994390 — Neuropathic Pain Intervention With tDCS in Brazilian Military Personnel (NeuBRAIN Trial) · NA · not yet recruiting
NCT07358832 — Neuromodulation Through Multisensory Stimulation for Visual Field Deficits in the Subacute Stage of Disease · NA · recruiting
NCT07331779 — Effect of tDCS Timing on Motor Recovery in Acute Stroke Rehabilitation · NA · not yet recruiting
NCT06972368 — Home-Based tDCS for Depression in BPD · NA · recruiting

Other recruiting trials for Alzheimer Disease

Currently open trials in the same condition.

NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03288363 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Benjamin CALVET
Last refreshed: 22 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03288363.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing